Indivior (LON: INDV) (Nasdaq: INDV) announced that it will cancel the secondary listing of its ordinary shares on the London Stock Exchange, with trading set to cease at 4 p.m. on 24 July 2025.
In a release on Monday, the company stated that it will maintain its primary listing on the Nasdaq.
The move follows a review by the board of Indivior, which considered liquidity, trading volumes, shareholder location, and the costs associated with dual listings.
The company explained that as of late May, 75% of Indivior’s share trading volume took place on Nasdaq, and over 70% of shareholders by value are based in the US.
“A single primary listing on Nasdaq best reflects the profile of Indivior's business,” said Chair David Wheadon. “[We] look forward to capitalizing on the expected benefits of this move, including reductions in cost and complexity.”
The company cited the growing importance of its US business, particularly SUBLOCADE, its long-acting treatment for opioid use disorder, and noted that over 80% of its net revenue is generated in the United States.
From 25 July, Indivior shares will no longer be tradeable on the LSE. However, the company stated that the delisting will not affect direct holders of its ordinary shares or those using US brokers and custodians.
The UK Takeover Code will continue to apply to Indivior for two years following the delisting.
Searching for the Perfect Broker?
Discover our top-recommended brokers for trading and investing in financial markets. Dive in and test their capabilities with complimentary demo accounts today!
- BlackBull 26,000+ Shares, Options, ETFs, Bonds, and other underlying assets – Read our Review
- Admiral Markets More than 4500 stocks & over 200 ETFs available to invest in – Read our Review
- Hargreaves Lansdown The company's website is easily understandable and accessible to a wide range of customers – Read our Review
YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY
